CardioMEMS Cost, Coverage & Reimbursement Explained

Understand CardioMEMS costs, Medicare coverage, and reimbursement. Rhythm360 helps practices build a sustainable, profitable CardioMEMS service line.

Key Takeaways For CardioMEMS Programs

The CardioMEMS HF System carries a Medicare device acquisition cost of $17,750 per unit, with an average selling price of $24,950, plus roughly $1,129 for the implant procedure and $68 per patient per month for monitoring.
Medicare coverage under NCD 20.36 is limited to approved clinical studies or Coverage with Evidence Development (CED), while commercial payers may classify the procedure as investigational and may deny coverage.
Correct CPT coding, including 33289 for implantation and 93297 for 30-day remote interrogation, prevents denials and revenue leakage from modifier misuse or duplicate billing.
Hidden operational costs arise from manual data retrieval across multiple device portals, which can erode program margins unless practices streamline workflows.
Rhythm360 consolidates CardioMEMS and multi-OEM device data into a single, vendor-neutral platform that automates CPT capture, documentation, and EHR integration to increase revenue and staff efficiency.

Talk With Rhythm360 About Your CardioMEMS Program

The Real CardioMEMS Cost Stack

A defensible CardioMEMS budget separates three cost buckets: device, procedure, and monitoring. Within each bucket, facility type, payer mix, and negotiated supply contracts determine where your practice lands in the range.

Device Acquisition: $17,750 (the Medicare price) per unit, with a manufacturer-reported average selling price of $24,950. Published estimates place the implanted sensor at upwards of $20,000 per patient, consistent with the range Abbott negotiates with health systems.
Implant Procedure: approximately $1,129, excluding the device, based on 2014 Medicare Professional Fees for the right heart catheterization and angiography (CPT codes 93451 and 93568). The procedure is a standard right heart catheterization that takes roughly 30 to 45 minutes. It can be performed via internal jugular or femoral venous access using a 12-French sheath.
Monthly Monitoring: in the base case of the 2016 cost-effectiveness analysis by Sandhu et al., the assumed monthly cost of CardioMEMS device management was $68 per patient (range $34–$136), though other analyses have used different estimates such as $47 per month. This figure reflects the reimbursable monitoring cost and does not capture the staff time required to retrieve, reconcile, and document data, which appears later as an operational cost.

The acquisition cost sets the baseline, while the billing pathway determines long-term financial performance. Correct CPT 33289 coding at implant and complete 30-day CPT 93297 capture without leakage define the revenue side of the model. For a deeper look at how CardioMEMS fits within the broader remote monitoring landscape, see our Cardiac Remote Monitoring: 2026 Guide To Devices & Costs.

Review Your CardioMEMS Cost Model With Rhythm360

Medicare And Commercial Coverage For CardioMEMS

CMS issued National Coverage Determination (NCD) 20.36, "Implantable Pulmonary Artery Pressure Sensors For Heart Failure Management," effective January 13, 2025, which created a national Medicare coverage framework for implantable pulmonary artery pressure sensors. Coverage under NCD 20.36 applies in the context of approved clinical studies or with the collection of additional clinical data under a Coverage with Evidence Development (CED) framework.

Because NCD 20.36 is a national determination, it is binding on all Medicare Administrative Contractors and supersedes any conflicting Local Coverage Determination. Medicare Advantage plans follow NCD policy, although individual plan administration can differ. Commercial payers set independent policies. Anthem Blue Cross Blue Shield of Virginia, for example, classifies CardioMEMS implantation as investigational and not medically necessary under its medical policy MED.00115 (published January 6, 2026, last reviewed November 6, 2025). Practices should confirm coverage with each commercial payer before scheduling implantation.

Clinical Criteria For CardioMEMS Candidates

The FDA initially approved the CardioMEMS HF System in May 2014 for individuals hospitalized for NYHA Class III heart failure in the past year and expanded approval in February 2022 to include NYHA Class II heart failure. Medicare coverage under NCD 20.36 aligns with the CED framework rather than FDA approval alone.

The typical qualifying candidate profile under the coverage criteria includes heart failure patients classified as NYHA Class III with a recent hospitalization or elevated natriuretic peptides on maximally tolerated guideline-directed medical therapy. The CardioMEMS HF System is contraindicated for individuals who are unable to take antiplatelet or anticoagulant medications for one month following implantation.

CardioMEMS Reimbursement Mechanics And 30-Day Monitoring

The reimbursement pathway for CardioMEMS uses one code family for the implant procedure and another for ongoing monitoring. Correct use of both code sets protects revenue and reduces denials.

CPT 33289: Transcatheter implantation of a wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography when performed. The national average Medicare payment is approximately $284.24, based on 8.51 total RVUs under the 2026 CMS Physician Fee Schedule, with locality adjustments ranging from approximately $290 in Georgia and Massachusetts to $367 in Alaska.
CPT 93297: Remote interrogation of an implantable cardiovascular monitor system covering up to 30 days of recorded physiologic data, including analysis of one or more recorded physiologic cardiovascular data elements from all internal and external sensors. This code applies to implantable cardiovascular physiologic monitors such as CardioMEMS. Subcutaneous cardiac rhythm monitors and implantable loop recorders use CPT 93298 instead.
Billing Options For CPT 93297: CPT 93297 can be billed globally, with modifier -26, or with modifier -TC, so a technical-only billing option exists for 93297.
The Professional/Technical Split: This split determines whether a practice actually collects on CardioMEMS monitoring. Duplicate global billing occurs when a monitoring company or device manufacturer has already billed 93297-TC directly to Medicare and the practice then submits the global 93297. One of the two claims will be denied, and the overlap typically surfaces months later on audit. Device-type mismatch and unbilled technical components also create denials and leakage.
Billing Frequency: CPT 93297 is reported once per 30-day period and is not reportable for a period shorter than 30 days. Practices should track each patient’s 30-day monitoring window from that patient’s own period end date rather than by calendar month.

These mechanics define how CardioMEMS monitoring turns into predictable revenue. For a full clinical and workflow overview of the CardioMEMS program, see our CardioMEMS Heart Failure Monitoring: Outcomes & Workflow guide.

See How Rhythm360 Tracks Every 30-Day Cycle

What Medicare Pays And What Patients Owe

The Medicare payment amount for CPT 33289 or CPT 93297 differs from the patient’s bill. Medicare pays its allowable amount to the provider, and the patient covers applicable coinsurance and deductibles under traditional Medicare.

Medicare Advantage plans apply their own cost-sharing structures, which vary by plan design but still sit on top of the Medicare coverage framework. Commercial plans negotiate separate fee schedules. They may also impose prior authorization requirements, step-edit criteria, or different cost-sharing tiers.

Practice administrators building a CardioMEMS financial model should estimate patient responsibility and payer-specific collection rates separately from the Medicare allowable. This distinction matters most when the patient population includes a significant Medicare Advantage or commercial share.

The Hidden Operational Cost Of CardioMEMS Data Management

Staff time spent retrieving CardioMEMS data from the Abbott Merlin.net PCN portal and reconciling it into the EHR creates a meaningful operational cost that rarely appears in device acquisition discussions. A CardioMEMS program following about 198 patients, like the one at Corewell Health in Grand Rapids, Michigan, is supported by three advanced practice providers who integrate data review into their daily schedules without dedicated monitoring time, plus nursing support. That model reflects a well-resourced program at a quaternary center.

The burden increases when a practice also manages Medtronic, Boston Scientific, Biotronik, and Abbott CIED data. Fragmentation across RPM platforms creates significant manual workload because providers must access multiple dashboards or manually input data rather than having data flow automatically into the EHR. Each portal login, manual data entry step, and report generation cycle adds labor cost that never appears on the device invoice but directly affects program margin.

Third-party support systems can help manage workload fluctuations and prevent omissions in medical fee claims. Documentation gaps can affect reimbursement even when appropriate services are provided, particularly when clinical activity occurs in one system and billing documentation in another. Operational design therefore links directly to reimbursement capture.

Rhythm360 addresses this operational gap. As a vendor-neutral, HIPAA-compliant platform, Rhythm360 consolidates CardioMEMS and multi-OEM device data from Medtronic, Boston Scientific, Abbott, Biotronik, and others into a single source of truth. It automates CPT capture and documentation and reduces critical alert response times by up to 80%. Practices using Rhythm360 have captured up to 300% more revenue through improved CPT code capture, better staff efficiency, and the addition of new RPM service lines.

Why CardioMEMS Costs Align With Clinical Value

The CHAMPION trial (Abraham et al., 2011, n=550) found a statistically significant 30% reduction in heart failure hospital readmissions at 6 months in the pulmonary artery pressure monitoring group versus standard care (HR 0.72; 95% CI 0.60–0.85; p=0.0002), with shorter heart failure-related hospital stays (2.2 vs. 3.8 days; p=0.02). A 2026 scoping review published in the European Heart Journal – Quality of Care and Clinical Outcomes concluded that CardioMEMS-guided heart failure management is cost-effective at accepted willingness-to-pay thresholds in the UK, continental Europe, and the USA, although the same review noted that cost-effectiveness depends on local device pricing.

This evidence base supports offering CardioMEMS as part of advanced heart failure care. The remaining question for practices involves building operational and billing infrastructure that can sustain the program financially.

What This Means For Your Practice

The CardioMEMS business case rests on three elements: acquisition cost, reimbursement capture, and operational overhead. Acquisition cost follows contract terms. Reimbursement capture depends on correct CPT 33289 coding at implant and disciplined 30-day CPT 93297 billing with the appropriate modifier split for every patient in the monitoring panel. Operational overhead represents the variable that many practices underestimate before launch.

Cardiology practices evaluating their monitoring infrastructure can choose among several platforms, including Murj, Implicity, Rhythm Management Group, and Octagos. Rhythm360 from RhythmScience is a vendor-neutral, HIPAA-compliant platform built for the multi-OEM environment that CardioMEMS programs face every day. It consolidates device data across manufacturers, automates CPT capture and documentation, and provides bi-directional EHR integration with Epic, Cerner, Athenahealth, eClinicalWorks, Greenway Health, and others to support stronger billing and revenue outcomes.

Explore Rhythm360 For CardioMEMS And CIED Monitoring

Conclusion: Turning CardioMEMS Into A Sustainable Service Line

The CardioMEMS device price often receives the most attention during early planning, yet long-term program performance depends more on coding accuracy and monitoring workflows. Financial outcomes hinge on correct CPT 33289 coding at implant and consistent CPT 93297 capture with the right modifier for every patient, every 30 days, without leakage. These requirements demand data-management infrastructure that consolidates CardioMEMS transmissions, automates billing documentation, and removes the multi-portal burden that drains staff time and produces missed claims.

Rhythm360 is designed for this environment. It consolidates CardioMEMS and multi-OEM device data into a single, vendor-neutral, HIPAA-compliant platform, automates CPT capture and documentation, and integrates bi-directionally with major EHR systems. Practices use Rhythm360 to reduce critical alert response times, improve staff efficiency, and expand RPM service lines while capturing more of the revenue that CardioMEMS monitoring generates.

Request A Rhythm360 Walkthrough For Your Team